|
시장보고서
상품코드
2040548
바이오프로세스 자동화 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 프로세스 단계별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Bioprocess Automation Market Size, Share & Trends Analysis Report By Product & Services, By Process Stage, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
바이오프로세스 자동화 시장 요약
세계의 바이오프로세스 자동화 시장 규모는 2025년에 86억 달러로 추정되며, 2033년까지 222억 달러에 달할 것으로 예측됩니다.
바이오의약품에 대한 수요 증가, AI 및 로봇공학의 발전, 규제 준수 필요성 등으로 인해 2026년부터 2033년까지 연평균 12.8%의 성장률을 기록할 것으로 예상됩니다.
바이오로직스에 대한 수요 증가
바이오로직스에 대한 수요 증가는 바이오프로세스 자동화 산업에서 가장 중요한 촉진요인 중 하나입니다. 지난 10년간, 단클론항체 개발, 백신 생산, 유전자 치료제 개발 및 기타 모든 생물학 제품의 개발이 급속히 확대되었습니다. 이는 이러한 치료법이 암, 자가면역질환, 희귀유전질환 등 복잡한 병증에 효과적으로 대처할 수 있기 때문입니다. 이러한 바이오로직스가 유효성을 유지하고 높은 품질을 유지하기 위해서는 제조 공정이 매우 엄격하게 관리되고, 확장 가능하며, 정밀해야 합니다. 기존의 수작업 및 반자동 생산 방식은 종종 노동 집약적이고 실수가 발생하기 쉬우며, 증가하는 시장 수요를 충족시키기에는 충분하지 않기 때문에 완전 자동화된 바이오프로세스 솔루션에 대한 수요가 증가하고 있습니다.
헬스케어 분야가 바이오의약품에 대한 의존도가 높아짐에 따라 바이오프로세스 자동화는 필수 불가결한 요소가 되고 있습니다. 로봇 공학, AI, 첨단 모니터링 기술을 활용하여 워크플로우 최적화, 일관성 향상, 처리량 증가, 비용, 변동성, 생산 시간 단축을 실현합니다.
효율성과 비용 절감의 필요성
비용 절감과 효율성에 대한 요구가 바이오프로세스 자동화 시장의 주요 원동력이 되고 있습니다. 바이오의약품 제조는 복잡하고 자원을 많이 소비하는 과정으로, 고도의 자격을 갖춘 직원, 세심한 모니터링 및 엄격한 프로토콜 준수가 요구되는 경우가 많습니다. 많은 인력을 필요로 하는 수동 및 반자동 공정은 작업 오류, 배치 실패, 제품 결함, 생산 비용 증가와 같은 생산 문제를 야기합니다. 자동화 시스템을 도입함으로써 기업은 생산성을 향상시키는 동시에 인적자원의 필요성을 줄이고 작업 오류를 줄여 보다 안정적인 생산 결과를 얻을 수 있습니다.
자동화는 생산성을 향상시키고, 운영 비용을 크게 절감하며, 신뢰성을 높입니다. 자동화된 바이오프로세스 시스템은 다운타임을 최소화하고, 자원 사용을 최적화하며, 생산 주기를 단축하는 기능을 갖추고 있어 제조업체가 증가하는 시장 수요에 보다 효과적으로 대응할 수 있도록 돕습니다. 비용에 대한 인식이 높아지는 헬스케어 환경에서 고품질 바이오의약품을 저비용으로 생산할 수 있는 능력은 기업의 경쟁력 유지에도 기여합니다. 그 결과, 비용 효율성과 업무 효율성에 대한 요구가 높아지면서 바이오프로세스 자동화 기술에 대한 전 세계 투자가 지속적으로 증가하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 시장 : 변수, 동향, 범위
제4장 제품 및 서비스별 사업 분석
제5장 프로세스 단계별 비즈니스 분석
제6장 최종 용도별 비즈니스 분석
제7장 바이오프로세스 자동화 시장 : 지역별 추정·동향 분석(제품 및 서비스별, 프로세스 단계별, 최종 용도별)
제8장 경쟁 구도
KSM 26.06.04Bioprocess Automation Market Summary
The global bioprocess automation market size was estimated at USD 8.6 billion in 2025 and is projected to reach USD 22.2 billion by 2033, growing at a CAGR of 12.8% from 2026 to 2033, driven by increasing demand for biologics, progress in AI and robotics, and the need for regulatory compliance.
Rising Demand for Biologics
The rising demand for biologics is among the most significant drivers of the bioprocess automation industry. Over the past decade, there has been a rapid expansion of monoclonal antibody development and vaccine production, gene therapy development, and all other biologic products because these treatments effectively address complicated medical conditions, which include cancer, autoimmune disorders, and rare genetic diseases. For these biologics to remain effective and to maintain high quality, manufacturing procedures must be extremely controlled, scalable, and precise. There is a significant need for fully automated bioprocess solutions because traditional manual or semi-automated production methods are frequently labor-intensive, prone to mistakes, and inadequate to meet the expanding market demand.
Bioprocess automation is becoming essential as healthcare increasingly relies on biologics. It optimizes workflows, enhances consistency, boosts throughput, and reduces costs, variability, and production time using robotics, AI, and advanced monitoring.
Need for Efficiency & Cost Reduction
The need for cost and efficiency reduction largely drives the market for bioprocess automation. Manufacturing biopharmaceuticals is a complicated and resource-intensive process that frequently requires highly qualified staff, careful observation, and strict protocol adherence. The manual and semi-automated processes, which need extensive human effort, lead to operational errors and result in production problems, including batch failures, product defects, and increased production costs. The implementation of automated systems enables businesses to achieve higher productivity levels while reducing their need for human workers and decreasing operational mistakes, which results in more reliable production outcomes.
Automation increases productivity, drastically reduces operating costs, and improves reliability. Manufacturers can more effectively meet growing market demand thanks to automated bioprocessing systems' ability to run continuously with little downtime, optimize resource usage, and speed up production cycles. In an increasingly cost-sensitive healthcare environment, the ability to produce high-quality biologics at a lower cost also helps businesses stay competitive. As a result, the need for cost-effectiveness and operational efficiency keeps driving global investments in bioprocess automation technologies.
Global Bioprocess Automation Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global bioprocess automation market based on product & service, process stage, end use, and region:
- Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
- Automation Consumables & Accessories
- Process Automation Hardware
- Software & Control Systems
- Integrated & Turnkey Solutions
- Services & Support
- Process Stage Outlook (Revenue, USD Million, 2021 - 2033)
- Upstream
- Downstream
- Process Development & Scale-up
- Fill/Finish & Packaging automation
- Quality Control & PAT
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical & biotech manufacturers
- CDMOs & CMOs
- Academic & research institutions
- Contract testing & analytical labs
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product & Services
- 1.2.2. Process Stage
- 1.2.3. End use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Details
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Impact Analysis
- 3.3.1.1. Rising demand for biologics
- 3.3.1.2. Need for efficiency and cost reduction
- 3.3.1.3. Advancements in AI, robotics, and IoT
- 3.3.1.4. Transition to single-use and continuous processing
- 3.3.2. Market Restraint Impact Analysis
- 3.3.2.1. High initial investment costs
- 3.3.2.2. Regulatory and compliance challenges
- 3.3.3. Market Opportunity Analysis
- 3.3.4. Market Challenge Analysis
- 3.3.1. Market Driver Impact Analysis
- 3.4. Case Study Insights
- 3.5. Business Environment Analysis
- 3.5.1. PESTLE Analysis
- 3.5.2. PORTER'S Five Forces Analysis
Chapter 4. Product & Services Business Analysis
- 4.1. Product & Services Segment Dashboard
- 4.2. Global Bioprocess Automation Market Product & Services, Movement Analysis
- 4.3. Global Bioprocess Automation Market Size & Trend Analysis, by Product & Services, 2021 to 2033 (USD Million)
- 4.4. Automation Consumables & Accessories
- 4.4.1. Global automation consumables & accessories market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.5. Process Automation Hardware
- 4.5.1. Global Process Automation Hardware market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.6. Software & Control Systems
- 4.6.1. Global software & control systems market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7. Integrated & Turnkey Solutions
- 4.7.1. Global integrated & turnkey solutions market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8. Services & Support
- 4.8.1. Global services & support market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Process Stage Business Analysis
- 5.1. Process Stage Segment Dashboard
- 5.2. Global Bioprocess Automation Market Process Stage, Movement Analysis
- 5.3. Global Bioprocess Automation Market Size & Trend Analysis, by Process Stage, 2021 to 2033 (USD Million)
- 5.4. Upstream
- 5.4.1. Global upstream market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.5. Downstream
- 5.5.1. Global downstream market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.6. Process Development & Scale-up
- 5.6.1. Global process development & scale-up market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.7. Fill/Finish & Packaging automation
- 5.7.1. Global fill/finish & packaging automation market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.8. Quality Control & PAT
- 5.8.1. Global quality control & PAT market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Global Bioprocess Automation Market End Use, Movement Analysis
- 6.3. Global Bioprocess Automation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 6.4. Pharmaceutical & biotech manufacturers
- 6.4.1. Global Pharmaceutical & biotech manufacturers market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5. CDMOs & CMOs
- 6.5.1. Global CDMOs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.6. Academic & research institutions
- 6.6.1. Global academic & research institutions market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7. Contract testing & analytical labs
- 6.7.1. Global contract testing & analytical labs market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.8. Others
- 6.8.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Bioprocess Automation Market: Regional Estimates and Trend Analysis, by Product & Services, Process Stage & End Use.
- 7.1. Regional Dashboard
- 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
- 7.3. North America
- 7.3.1. North America bioprocess automation market, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Competitive Scenario
- 7.3.2.4. Regulatory Framework
- 7.3.2.5. U.S. bioprocess automation market, 2021 - 2033 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. Canada bioprocess automation market, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Mexico bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4. Europe
- 7.4.1. Europe bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.2. UK
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Regulatory Framework
- 7.4.2.5. UK bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.3. Germany
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Germany bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. France bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. Italy bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Spain bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Denmark bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Target Disease Prevalence
- 7.4.8.3. Competitive Scenario
- 7.4.8.4. Regulatory Framework
- 7.4.8.5. Sweden bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Target Disease Prevalence
- 7.4.9.3. Competitive Scenario
- 7.4.9.4. Regulatory Framework
- 7.4.9.5. Norway bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.2. Japan
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Regulatory Framework
- 7.5.2.5. Japan bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.3. China
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. China bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Regulatory Framework
- 7.5.4.5. India bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.5. Singapore
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Regulatory Framework
- 7.5.5.5. Singapore bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.6. Australia
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Competitive Scenario
- 7.5.6.4. Regulatory Framework
- 7.5.6.5. Australia bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.7. Thailand
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Competitive Scenario
- 7.5.7.4. Regulatory Framework
- 7.5.7.5. Thailand bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.8. South Korea
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Competitive Scenario
- 7.5.8.4. Regulatory Framework
- 7.5.8.5. South Korea bioprocess automation market, 2021 - 2033 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America bioprocess automation market, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Regulatory Framework
- 7.6.2.5. Brazil bioprocess automation market, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. Argentina bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7. MEA
- 7.7.1. MEA bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Competitive Scenario
- 7.7.2.4. Regulatory Framework
- 7.7.2.5. South Africa bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Competitive Scenario
- 7.7.3.4. Regulatory Framework
- 7.7.3.5. Saudi Arabia bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.4. UAE
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Target Disease Prevalence
- 7.7.4.3. Competitive Scenario
- 7.7.4.4. Regulatory Framework
- 7.7.4.5. UAE bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Target Disease Prevalence
- 7.7.5.3. Competitive Scenario
- 7.7.5.4. Regulatory Framework
- 7.7.5.5. Kuwait bioprocess automation market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. Thermo Fisher Scientific Inc.
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Sartorius AG
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Parker Hannifin Corp
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Merck KGaA
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Eppendorf SE
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. SIA Bioreactors.net
- 8.4.6.1. Overview
- 8.4.6.2. Product Benchmarking
- 8.4.6.3. Strategic Initiatives
- 8.4.7. Senieer
- 8.4.7.1. Overview
- 8.4.7.2. Product Benchmarking
- 8.4.7.3. Strategic Initiatives
- 8.4.8. Getinge
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Repligen Corporation
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.1. Thermo Fisher Scientific Inc.
